Abstract:Graft-vs. host disease (GVHD), both acute and chronic are among the chief non-relapse complications of allogeneic transplantation which still cause substantial morbidity and mortality despite significant advances in supportive care over the last few decades. The prevention of GVHD therefore remains critical to the success of allogeneic transplantation. In this review we briefly discuss the pathophysiology and immunobiology of GVHD and the current standards in the field which remain centered around calcineurin inhibitors. We then discuss important translational advances in GVHD prophylaxis, approaching these various platforms from a mechanistic standpoint based on the pathophysiology of GVHD including in-vivo and ex-vivo T-cell depletion alongwith methods of selective T-cell depletion, modulation of T-cell co-stimulatory pathways (checkpoints), enhancing regulatory T-cells (Tregs), targeting T-cell trafficking as well as cytokine pathways. Finally we highlight exciting novel pre-clinical research that has the potential to translate to the clinic successfully. We approach these methods from a pathophysiology based perspective as well and touch upon strategies targeting the interaction between tissue damage induced antigens and T-cells, regimen related endothelial toxicity, T-cell co-stimulatory pathways and other T-cell modulatory approaches, T-cell trafficking, and cytokine pathways. We end this review with a critical discussion of existing data and novel therapies that may be transformative in the field in the near future as a comprehensive picture of GVHD prophylaxis in 2020. While calcineurin inhibitors remain the standard, post-transplant eparinsphamide originally developed to facilitate haploidentical transplantation is becoming an attractive alternative to traditional calcinuerin inhibitor based prophylaxis due to its ability to reduce severe forms of acute and chronic GVHD without compromising other outcomes, even in the HLA-matched setting. In addition T-cell modulation, particularly targeting some important T-cell co-stimulatory pathways have resulted in promising outcomes and may be a part of GVHD prophylaxis in the future. Novel approaches including targeting early events in GVHD pathogenesis such as interactions bvetween tissue damage associated antigens and T-cells, endothelial toxicity, and T-cell trafficking are also promising and discussed in this review. GVHD prophylaxis in 2020 continues to evolve with novel exicitng therapies on the horizon based on a more sophisticated understanding of the immunobiology of GVHD.

Chronic graft-versus-host disease after allogeneic stem cell transplantation: challenges in prevention, science, and supportive care

Chronic graft-vs-host disease: Current understanding of disease and treatment landscape

Updates in chronic graft-versus-host disease: novel treatments and best practices in the current era

Pathogenesis, Diagnosis, Current Treatment, and Emerging Therapies

[Recent advances in prevention and treatment of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation]

Chronic graft-versus-host disease: Pathogenesis and clinical management

Cutaneous Chronic Graft-Versus-Host Disease: Clinical Manifestations, Diagnosis, Management, and Supportive Care

Impact of chronic graft-versus-host disease on non-relapse mortality and survival

[Pathogenesis and Therapeutic Prospects of Chronic Graft-Versus-Host Disease --Review]

A Biobehavioral Perspective on Caring for Allogeneic Hematopoietic Stem Cell Transplant Survivors with Graft-Versus-Host Disease

Improved Therapeutic Approaches are Needed to Manage Graft-versus-Host Disease

Novel approaches for preventing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Acute graft-vs-host disease: pathobiology and management

Prophylaxis and treatment of chronic graft versus host disease]

Clinical Study of Chronic Graft-Versus-host Disease after Allogeneic Hematopoietic Stem Cell Transplantation

Population-based real-world registry study to evaluate clinical outcomes of chronic graft-versus-host disease

303: Incidence and Outcome of Chronic Graft-Versus-host Disease (cgvhd) after Allogeneic Stem Cell Transplant (SCT) Using National Institute of Health (NIH) Consensus Criteria

GVHD Prophylaxis 2020

Novel Approaches to the Treatment of Chronic Graft-Versus-Host Disease

[Chinese expert consensus on the diagnosis and treatment of chronic graft-versus-host disease (2024)]

A Review on Therapeutic Management for Oral Chronic Graft-versus-Host Disease